bioRxivCancer Biology
Quantitative proteomics identifies novel PIAS1 protein substrates involved in cell migration and motility
C. Li, F. P. McManus, C. Plutoni, C. M. Pascariu, T. Nelson, L. E. Alberici Delsin, G. Emery, P. Thibault
Abstract
The Protein Inhibitor of Activated STAT 1 (PIAS1) is an E3 SUMO ligase that plays important roles in various cellular pathways, including STAT signaling, p53 pathway, and the steroid hormone signaling pathway. PIAS1 can SUMOylate PML (at Lys-65 and Lys-160) and PML-RAR promoting their ubiquitin-mediated degradation. Increasing evidence shows that PIAS1 is overexpressed in various human malignancies, including prostate and lung cancers. To understand the mechanism of action of PIAS1, we developed a quantitative SUMO proteomic approach to identify potential substrates of PIAS1 in a system-wide manner. Our analyses enabled the profiling of 983 SUMO sites on 544 proteins, of which 204 SUMO sites on 123 proteins were identified as putative PIAS1 substrates. These substrates are involved in different cellular processes, such as transcriptional regulation, DNA binding and cytoskeleton dynamics. Further functional studies on Vimentin (VIM), a type III intermediate filament protein involved in cytoskeleton organization and cell motility, revealed that PIAS1 exerts its effects on cell migration and cell invasion through the SUMOylation of VIM at Lys-439 and Lys-445 residues. VIM SUMOylation was necessary for its dynamic disassembly, and cells expressing a non-SUMOylatable VIM mutant showed reduced levels of proliferation and migration. Our approach not only provides a novel strategy for the identification of E3 SUMO ligase substrates, but also yields valuable biological insights into the unsuspected role of PIAS1 and VIM SUMOylation on cell motility.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of PIM1 substrates reveals a role for NDRG1 in prostate cancer cellular migration and invasion
R. J. Ledet, S. Ruff, … M. J. Garabedian·bioRxiv·Jan 21, 2020
- Integrative Proteomic Analysis Implicates Inhibition of Intracellular Protein Trafficking in Therapy-Induced Migrastasis in Prostate Cancer
Weining Chen, Saadyeh Rashidi, … Raymond C. Bergan·ProteomesPeer-reviewed·Aug 28, 2026
- PI31 is a positive regulator of 20S immunoproteasome assembly
Jason Wang, Abbey Kjellgren, George Demartino·Journal of Cell SciencePeer-reviewed·May 8, 2025
- Differential interactions of the proteasome inhibitor PI31 with constitutive and immuno-20S proteasomes
J. Wang, A. Kjellgren, G. N. DeMartino·bioRxiv·Dec 11, 2023
- Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1
Merav D. Shmueli, Yongfeng Tao, … Yifat Merbl·bioRxiv·Oct 16, 2026
- SUMO Activated Target Traps (SATTs) enable the identification of a comprehensive E3-specific SUMO proteome.
Daniel Salas‐Lloret, Nicolette S. Jansen, … Román González‐Prieto·Science AdvancesPeer-reviewed·Aug 2, 2023